Sugi Predict

Sugi Predict / Compounds / SCHEMBL906459

SCHEMBL906459

SCHEMBL906459

Brc1cccc(C2CCC2)n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HTR1A P08908 2/20 0.41
▸ DRD2 P14416 2/20 0.41
▸ HTR2A P28223 2/20 0.41
▸ HTR7 P34969 2/20 0.41
▸ CNR2 P34972 7/20 0.39
▸ CHRNA7 P36544 1/20 0.38
▸ POLB P06746 1/20 0.35
▸ CASP3 P42574 1/20 0.35
▸ SENP7 Q9BQF6 1/20 0.35
▸ SENP6 Q9GZR1 1/20 0.35
▸ PDE9A O76083 1/20 0.34
▸ FFAR4 Q5NUL3 2/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.33
▸ PDE8A O60658 1/20 0.32
▸ IDH1 O75874 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13891 0.96 HTR1A (0.44) HTR1ADRD2HTR2AHTR7CNR2
SCHEMBL9938077 0.91 IDH1 (0.36) HTR1ADRD2HTR2AHTR7CNR2
SCHEMBL30429137 0.91 IDH1 (0.36) HTR1ADRD2HTR2AHTR7CNR2
SCHEMBL13490498 0.81 DRD2 (0.44) DRD2
SCHEMBL25121130 0.80 USP7 (0.41) HTR1ADRD2PDE9A
SCHEMBL23028116 0.78 HTR1A (0.53) HTR1ADRD2HTR2AHTR7CNR2
SCHEMBL24565129 0.78 HTR1A (0.53) HTR1ADRD2HTR2AHTR7CNR2
SCHEMBL21815396 0.78 CHRNB4 (0.38) HTR2A
SCHEMBL31543163 0.78 KDM1A (0.30) —
SCHEMBL22234824 0.76 CNR2 (0.37) HTR1ADRD2CNR2CHRNA7PDE8A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 — — US disclosed
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2020-06-02 — — US disclosed
CN-109608449-A Compound as type III receptor tyrosine kinase inhibitors 阵列生物制药公司 2019-04-12 — — CN disclosed
CN-105924437-B Compound as type III receptor tyrosine kinase inhibitors 阵列生物制药公司 2018-11-30 — — CN disclosed
US-20180086758-A1 SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2018-03-29 — — US disclosed
US-9809590-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-11-07 — — US disclosed
EP-2948442-B1 PYRROLIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2016-10-26 — — EP disclosed
CN-105924437-A Compounds As Type III Receptor Tyrosine Kinase Inhibitors 阵列生物制药公司 2016-09-07 — — CN disclosed
EP-2797885-B1 NEW AZETIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INT (DE) 2016-08-10 — — EP disclosed
CN-103347882-B Substituted N- (1H-indazol-4-yl) imidazo [1,2-a ] pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-05-11 — — CN disclosed
US-20130172312-A1 Azetidine Derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 — — US disclosed
US-20130172312-A1 Azetidine Derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 — — US disclosed
CN-101959883-B 3-indazolyl-4-pyridylisothiazoles LILLY CO ELI 2013-01-30 — — CN disclosed
WO-2012082689-A1 SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2012-06-21 — — WO disclosed
EP-2276759-B1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES LILLY CO ELI (US) 2011-10-19 — — EP disclosed
US-7932274-B2 3-indazolyl-4-pyridylisothiazoles ELI LILLY AND COMPANY (US) 2011-04-26 — — US disclosed
EP-2276759-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES Eli Lilly & Company (US) 2011-01-26 — — EP disclosed
CN-101959883-A 3-indazolyl-4-pyridylisothiazoles LILLY CO ELI 2011-01-26 — — CN disclosed
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY 2009-10-08 — — US disclosed
WO-2009123855-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES ELI LILLY AND COMPANY (US) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172312-A1 Azetidine Derivatives GPR119, LIPE, LPL HTR1A 284/4885DRD2 41/4885HTR2A 73/4885
US-10669269-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors MUSK, FGFR1, PDGFRA HTR1A 1110/4885DRD2 4046/4885HTR2A 1805/4885
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 HTR1A 3136/4885DRD2 4652/4885HTR2A 2144/4885
US-20090253750-A1 3-INDAZOLYL-4-PYRIDYLISOTHIAZOLES CYP3A4, IPO4, JAK3 HTR1A 1931/4885DRD2 2710/4885HTR2A 1922/4885
US-20180086758-A1 SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS LTK, MUSK, FGFR1 HTR1A 1239/4885DRD2 4426/4885HTR2A 1560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.